Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 40,164 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James Hamilton sold 40,164 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. The trade was a 18.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Arrowhead Pharmaceuticals Stock Down 5.8%

ARWR stock traded down $3.91 during trading hours on Monday, hitting $63.88. The company’s stock had a trading volume of 2,692,485 shares, compared to its average volume of 2,131,468. The stock has a 50 day moving average price of $55.20 and a two-hundred day moving average price of $35.35. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The company has a market capitalization of $8.68 billion, a PE ratio of -798.40 and a beta of 1.21. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

ARWR has been the topic of several analyst reports. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Bank of America upped their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Piper Sandler raised their price objective on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 20th. Finally, Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.89.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth $576,000. Marshall Wace LLP raised its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares in the last quarter. Moody Lynn & Lieberson LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $213,000. HBK Sorce Advisory LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $2,823,000. Finally, Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at about $30,414,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.